Processa Pharmaceuticals (NASDAQ:PCSA) Rating Reiterated by Maxim Group

Processa Pharmaceuticals (NASDAQ:PCSA)‘s stock had its “hold” rating reissued by investment analysts at Maxim Group in a note issued to investors on Friday, Benzinga reports.

Processa Pharmaceuticals Trading Up 1.0 %

Shares of NASDAQ PCSA traded up $0.00 during midday trading on Friday, reaching $0.42. 476,549 shares of the company were exchanged, compared to its average volume of 720,913. The stock has a fifty day simple moving average of $0.33 and a 200 day simple moving average of $0.45. The stock has a market cap of $10.35 million, a P/E ratio of -0.36 and a beta of 0.11. Processa Pharmaceuticals has a 1 year low of $0.18 and a 1 year high of $2.24.

Processa Pharmaceuticals (NASDAQ:PCSA) last announced its earnings results on Monday, November 13th. The company reported ($0.08) earnings per share for the quarter.

Institutional Trading of Processa Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Citadel Advisors LLC purchased a new stake in shares of Processa Pharmaceuticals in the second quarter valued at approximately $141,000. Two Sigma Securities LLC purchased a new position in shares of Processa Pharmaceuticals in the 1st quarter valued at about $31,000. Raymond James Financial Services Advisors Inc. acquired a new stake in shares of Processa Pharmaceuticals in the fourth quarter valued at about $54,000. Dimensional Fund Advisors LP purchased a new stake in Processa Pharmaceuticals during the third quarter worth about $28,000. Finally, Renaissance Technologies LLC acquired a new position in Processa Pharmaceuticals during the second quarter worth about $33,000. Hedge funds and other institutional investors own 5.67% of the company’s stock.

Processa Pharmaceuticals Company Profile

Processa Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on developing the chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.